Rocket Lab heads into the final day of September with its stock down 3.2% on the week to $69.70, even as short sellers quietly reduce their exposure and the analyst consensus remains firmly in bull territory.
The short-side picture is less pressured than it might appear. Short interest dropped 7.6% over the past week to 46.1 million shares, representing 8.6% of the free float. That is a meaningful absolute level, but the direction of travel matters: shorts have been covering since a mid-week peak around September 22 to 23 when shares short briefly climbed toward 49.9 million. The lending market is relaxed. Availability has widened to 267%, meaning there are nearly three shares available to borrow for every one currently out on loan, well above the 52-week tightest reading of 173%. Borrowing cost has also eased, with the cost to borrow dropping 20% over the week to 0.40%, its lowest in a month. No squeeze mechanics are at work here. Options sentiment is similarly calm: the put/call ratio at 0.71 sits marginally below its 20-day average of 0.72, with a z-score of negative 0.55, pointing to neither unusual fear nor complacency heading into October. The ORTEX short score at 54.4 is mid-range and broadly flat over the past two weeks, consistent with a stock in a holding pattern rather than one under active attack.
The Street is bullish but not uniformly so, and the gap between targets and price does much of the work. The consensus is a buy, with a mean price target of $109.37 against the current price of $69.70, implying roughly 57% to the average. Raymond James initiated coverage on September 11 with an Outperform and an $80 target, the most cautious new entrant, while Cantor Fitzgerald lifted its target to $122 following the August 10 earnings release. BofA Securities trimmed its target slightly to $110 from $115 at the end of August but maintained its Buy rating. Citizens and Roth Capital both carry targets of $130. The bull case centres on Rocket Lab's pivot from a pure launch provider toward a vertically integrated space platform: Neutron, targeting around 13,000 kg payload capacity, is in final assembly for a Q4 2026 launchpad delivery, and the proposed $8 billion acquisition of Iridium adds 66 operational satellites, scarce L-band spectrum and 2.55 million subscribers. The bear case is simpler: the stock is priced for strong execution in a capital-intensive business where Neutron delays, budget cuts and integration risk all leave limited margin for error. Valuation multiples reflect the tension, with an EV/EBITDA above 600x and a trailing P/E in the thousands, the company's earnings power is entirely a forward story. EPS surprise ranks in the 90th percentile, and the 30-day EPS momentum factor sits at the 99th percentile, meaning near-term estimate revisions have been running strongly positive. The 90-day EPS momentum factor, however, has collapsed to the 1st percentile, a sharp reversal that suggests the upgrade cycle may have stalled after August's print.
Institutional and insider flows tell a mixed story. BlackRock added 2.6 million shares in August and now holds 6.8% of the company. JP Morgan Asset Management added 2.6 million shares as recently as September 1. T. Rowe Price built a position, adding 3.3 million shares. On the other side of the ledger, Invesco entered the register with 14.6 million shares added as of June 30, a notable new position. Insider activity over the past 90 days shows net selling of approximately 3.6 million shares worth over $312 million. The CFO Adam Spice sold around 140,000 shares on September 2 and the COO Frank Klein sold a combined 35,500 shares on August 27. All filings were made under pre-arranged 10b5-1 plans, which reduces their signalling value as expressions of near-term conviction. On the activist register, VK Services filed a Schedule 13D/A in February 2026 disclosing a 6.5% stake of 34.9 million shares, trimmed from 9.0% in October 2025. CEO and founder Peter Beck last disclosed a 7.51% stake in March 2026, down from 10.02% previously. ORTEX carries Schedule 13D on the register as active, and as always these are as-last-disclosed around the 5% threshold: holders dropping below may exit without a further filing.
The peer group amplified the week's weakness rather than cushioning it. LUNR fell 10.4% on the week and RDW dropped 8.8%, both harder hit than Rocket Lab's 3.2% decline. VOYG was the hardest hit among correlated names, down 18.1%. Rocket Lab's relative resilience against a sector-wide retreat is consistent with its higher institutional ownership and a more advanced product roadmap than most peers. After the most recent earnings on August 10, the stock fell 3.4% on the day and was essentially flat five sessions later, the prior quarter's release in May produced a 10.7% one-day gain and a 7.1% five-day move. The next scheduled print is November 10.
What to watch most closely is Neutron: any update on the launchpad delivery timeline, the Iridium acquisition regulatory process, and whether the 30-day EPS momentum revival can broaden back into the 90-day picture before the November earnings date.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
